Drug intelligence / Profile preview

SKB107

Development stage
Phase 1
Lead developer
Kelun-Biotech
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration
Intravenous
01

Overview

SKB107 is a radionuclide-drug conjugate (RDC) developed for the treatment of bone metastases in solid tumors. It is the first RDC clinical project from Sichuan Kelun-Biotech Biopharmaceutical and was jointly developed with Professor Chen Yue’s team at the Affiliated Hospital of Southwest Medical University. The drug utilizes a small molecule as its targeting ligand, which is combined with specialized conjugation technology, a chelator, and a therapeutic radionuclide. This design allows SKB107 to selectively target bone metastases, delivering cytotoxic radiation directly to tumor sites while minimizing damage to normal tissues. Compared to traditional external radiation therapy and conventional bone-modifying drugs, SKB107 aims for higher efficacy in killing tumor cells within bones and improved safety by reducing off-target effects[3][4][5][7].

Other names
68Ga/177Lu-DOTA-IBA镥177-TBM-001

Beyond the preview

Go deeper on SKB107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKB107.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call